Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy
Executive Summary
Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.
You may also be interested in...
Perrigo Adds Good Start Brand In $230M Statement On Boosting Infant Formula Production Capacity
Good Start formula line marketed in US and in Canada will move to Perrigo from Nestle along with a formula plant in Wisconsin, where Perrigo will expand current 29mil pound annual production capacity to 36m within 18 months. Good Start available in US as part of iconic Gerber brand and under Nestle brand in Canada.
Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions
From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.
Perrigo Has First US Approval For OTC Omeprazole Mini-Capsule
Capsule is 70% smaller than tablets of omeprazole currently available in Prilosec OTC and generic equivalents, including formulations Perrigo provides for its private label and store brand customers.